Novartis, QLT Will Expand Visudyne Population Following Approvable Letter
This article was originally published in The Gray Sheet
Executive Summary
Novartis Ophthalmics' submission to FDA of interim data analyses from a Phase II study evaluating its Visudyne photodynamic therapy to treat ocular histoplasmosis syndrome (OHS) is likely to secure approval of its supplemental new drug application.